Volcanes activos en Venus
En este Short conoceremos cómo ha podido descubrirse actividad volcánica actual en Venus. …
Uncategorized
BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference
BioArctic AB and its partner Eisai has presented new findings on lecanemab, an anti-amyloid beta protofibril antibody for the treatment of Alzheimer’s disease, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders.
BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference Read More »
XNK Receives EU Tissue Establishment Certificate
XNK Therapeutics announced that it has been approved as an EU Tissue Establishment.
XNK Receives EU Tissue Establishment Certificate Read More »
Harbour BioMed Reports Full Year 2022 Financial Results
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual results of full year 2022.
Harbour BioMed Reports Full Year 2022 Financial Results Read More »
The Sino-American Pharmaceutical Professionals Association-Greater Philadelphia (SAPA-GP) Hosted the 2023 Annual Conference
The Sino-American Pharmaceutical Professionals Association-Greater Philadelphia hosted its 21st Annual Conference at the Sheraton Valley Forge Hotel northwest of Philadelphia.
Wyss Center Geneva Appoints Erwin Böttinger as new Chief Executive Officer
The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med. Erwin Böttinger as its new Chief Executive Officer.
Wyss Center Geneva Appoints Erwin Böttinger as new Chief Executive Officer Read More »
GC Cell and New Management Embarking on a New Chapter
GC Cell, a Korean biotech company, announced on Mar. 28th that it had held the 12th General Shareholders’ Meeting at GC Biopharma R&D Center in Yongin, Gyeonggi-do of South Korea and resolved some major agenda items, including the appointment of inside directors.
GC Cell and New Management Embarking on a New Chapter Read More »
Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124
Orexo AB, announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose, is delayed to late 2024 from previously first half of 2024, if approved by the US Food and Drug Administration according to their ordinary timelines.
Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124 Read More »
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
RELIEF THERAPEUTICS Holding SA announces the appointment of world-renowned gene therapy pioneer Guangping Gao, Ph.D. as the chair of the Company’s newly formed scientific advisory board.
Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program
Innate Pharma SA announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.